Phase IIb study ZYN002 in adult with refractory focal epilepsy.

Trial Profile

Phase IIb study ZYN002 in adult with refractory focal epilepsy.

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2018 New trial record
    • 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, company intends to initiate this trial in the second half of 2018. The design of this study will be modified from the STAR 1 and STAR 2 trial design which includes increase in the number of patients enrolled, baseline seizure frequency, length of the study and also changes in randomization methodologies utilized.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top